Concentrated Radionuclide Complex Solutions With Sequential Stabilization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing radiopharmaceutical drug products suffer from radiolytic degradation during manufacturing and storage, necessitating on-site preparation and administration, and concentrated solutions face challenges of patient discomfort and physiological tolerability due to ethanol content or dilution requirements.
Innovation Solution
A process involving the formation of a radionuclide complex with DOTA-TATE or DOTA-TOC using gentisic acid and ascorbic acid as stabilizers, followed by sequential addition of stabilizers to create a highly concentrated, stable, and ready-to-use pharmaceutical solution.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If the radiopharmaceutical drug product is produced in high concentration, then patient convenience and tolerability are improved, but radiolytic degradation increases
Solution Approach 1:
The patent applies preliminary action by performing stabilizer addition and complexation steps before the radiopharmaceutical product is ready for use. Gentisic acid and ascorbic acid are added to the radionuclide solution prior to complexation with the peptide, creating a stable complex that resists radiolytic degradation during storage and administration. This advance preparation allows the product to be manufactured at high concentration while maintaining stability.
Solution Approach 2:
The patent uses gentisic acid and ascorbic acid as intermediary substances that mediate between the radionuclide and the peptide complex. These stabilizers act as intermediaries that protect the radiopharmaceutical complex from radiolytic degradation by scavenging free radicals generated during storage, enabling high concentration formulations to remain stable without requiring dilution.
2Reliability
If stabilizers are added to prevent radiolysis, then chemical stability is improved, but solubility issues and precipitation may occur
Solution Approach 1:
The patent applies parameter changes by carefully controlling the pH, concentration, and sequence of adding stabilizers during the complexation process. Gentisic acid is added first to establish appropriate conditions, followed by ascorbic acid, with each addition carefully managed to maintain solubility while achieving the desired stabilizing effect. This controlled parameter adjustment prevents precipitation while ensuring chemical stability.
3Reliability
If the drug product is stored at low temperatures, then radiolytic degradation is reduced, but manufacturing complexity and cost increase
Solution Approach 1:
The patent applies self-service by incorporating stabilizers that automatically protect the radiopharmaceutical complex from radiolytic degradation during storage at ambient temperatures. The gentisic acid and ascorbic acid system provides self-protecting functionality, eliminating the need for external cold chain infrastructure and complex temperature control systems, thereby simplifying storage and distribution.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The solution achieves high chemical and radiochemical stability, allowing for commercial-scale production and shipment of a ready-to-use radiopharmaceutical product with improved patient convenience and tolerability, maintaining stability at ambient or elevated temperatures for at least 72 hours.
Implementation Method 1
the decay of the radionuclide occurs constantly, e.g. also during the manufacturing and during storage of the drug product, and the released high energy emissions induce the cleavage of the chemical bonds of the molecules which form part of the drug product. This is often referred to as radiolysis or radiolytic degradation.
Implementation Method 2
forming a complex of (i) 177Lu or 68Ga with (ii) DOTA-TATE or DOTA-TOC in the presence of gentisic acid and ascorbic acid as stabilizers
Data Source
AI summary
The present invention relates to radionuclide complex solutions of high concentration and of high chemical stability, that allows their use as drug product for diagnostic and/or therapeutic purposes. The stability of the drug product is achieved by at least one stabilizer against radiolytic degradation. The use of two stabilizers introduced during the manufacturing process at different stages was found to be of particular advantage.